News Releases

News Release | U.S. PIRG | COVID-19, Democracy

This week in COVID-19 voting news

U.S. PIRG and its state affiliates are working to make sure that every eligible American voter has the ability to participate in democracy, even during a pandemic. We have called on states to ensure safe elections in November, with emergency expansion of vote by mail, sanitized and socially distant polling places and other measures. This weekly update highlights the work we’re doing on the COVID-19 voting front, and other important developments in the news.

News Release | U.S. PIRG

U.S. PIRG, Environment America, and other advocacy groups file federal lawsuit over new process to determine the stringency of energy efficiency standards

U.S. PIRG, Environment America, and other advocacy groups filed a lawsuit Friday to protect energy efficiency standards. The suit challenges the Department of Energy’s new rule that changes the process by which it determines the stringency of energy efficiency standards.

News Release | U.S. PIRG | COVID-19

Patient procedures are commonly delayed while manufacturers block others from repairing equipment

 Many hospitals have to postpone patient care while waiting on manufacturers’ technicians according to a new survey finding. 

News Release | U.S. PIRG Education Fund | Consumer Protection

COVID-19 pandemic worsens existing consumer problems with car buying

Consumer complaints to the Consumer Financial Protection Bureau (CFPB) regarding vehicle loans and leases have increased sharply during the coronavirus pandemic, according to a new report by the U.S. PIRG Education Fund and Frontier Group. The analysis suggests that consumers are facing abusive and deceptive practices from the automobile lending industry.

News Release | U.S. PIRG | Health Care

Humira manufacturer’s efforts to block generic options challenged in court

The maker of Humira, the world’s best-selling drug, faces a new legal challenge over alleged anticompetitive tactics. Monday, U.S. PIRG filed an amicus brief in the 7th Circuit Court of Appeals arguing that AbbVie’s strategies of reverse payment settlements and creating “patent thickets” have delayed the entry of biologically similar generic drugs (biosimilars) onto the market, costing Americans billions of dollars. 

Pages

Subscribe to More News

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code



U.S. PIRG is part of The Public Interest Network, which operates and supports organizations committed to a shared vision of a better world and a strategic approach to social change.